Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma

Cancer Research

Volumn 72, Issue 19, 2012, Pages 4909-4919

  Cruz Muñoz, William ^a   Jaramillo, Maria L ^c   Man, Shan ^a   Xu, Ping ^a   Banville, Myriam ^c   Collins, Catherine ^c   Nantel, Andre ^c   Francia, Giulio ^a   Morgan, Sherif S ^d   Cranmer, Lee D ^d   O'Connor McCourt, Maureen D ^c   Kerbel, Robert S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; BCL2 RELATED PROTEIN A1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR B; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; CENTRAL NERVOUS SYSTEM METASTASIS; DISEASE ASSOCIATION; DISEASE MODEL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTRACRANIAL TUMOR; MELANOMA; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN INTERACTION; SPONTANEOUS CENTRAL NERVOUS SYSTEM METASTASIS; TREATMENT OUTCOME; TUMOR GROWTH; VISCERAL METASTASIS;

ANIMALS; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICE; MICE, SCID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLIDINES; RECEPTOR, ENDOTHELIN B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867125382     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2194     Document Type: Article

References (39)

1. Maher EA, Mietz J, Arteaga CL, DePinho RA, Mohla S. Brain metastasis: opportunities in basic and translational research. Cancer Res 2009;69:6015-20.
2. Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 2006;19:19 -25.
3. Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev 2004;30:515-20. (Pubitemid 39157852)
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507 -16.
5. Vultur A, Villanueva J, Herlyn M. BRAF inhibitor unveils its potential against advanced melanoma. Cancer Cell 2010;18:301-2.
6. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007;13:1648-55. (Pubitemid 46952930)
7. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005;75:5-14. (Pubitemid 41548673)
8. Soffietti R, Ruda R, Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol 2008;20: 676 - 84.
9. Aragon-Ching JB, Zujewski JA. CNS metastasis: an old problem in a new guise. Clin Cancer Res 2007;13:1644-7. (Pubitemid 46952929)
10. Tarhini AA, Agarwala SS. Management of brain metastases in patients with melanoma. Curr Opin Oncol 2004;16:161-6. (Pubitemid 38402531)
11. Mayer M. A patient perspective on brain metastases in breast cancer. Clin Cancer Res 2007;13:1623-4. (Pubitemid 46952924)
12. Palmieri D, Chambers AF, Felding- Habermann B, Huang S, Steeg PS. The biology of metastasis to a sanctuary site. Clin Cancer Res 2007;13:1656-62. (Pubitemid 46957363)
13. Cruz-Munoz W, Man S, Xu P, Kerbel RS. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res 2008;68:4500-5.
14. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res 2001;2:90-101. (Pubitemid 34187913)
15. Montgomery JP, Patterson PH. Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor. BMC Cancer 2008:8:354.
16. Rosano L, Spinella F, Genovesi G, Di Castro V, Natali PG, Bagnato A. Endothelin-B receptor blockade inhibits molecular effectors of melanoma cell progression. J Cardiovasc Pharmacol 2004;44(Suppl 1): S136 -9.
17. Chichorro JG, Zampronio AR, Rae GA. Endothelin ET(B) receptor antagonist reduces mechanical allodynia in rats with trigeminal neuropathic pain. Exp Biol Med (Maywood) 2006;231:1136-40. (Pubitemid 43845593)
18. Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007;13: 1663-74. (Pubitemid 46952931)
19. Kemper EM, Verheij M, Boogerd W, Beijnen JH, van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 2004;40: 1269-74. (Pubitemid 38526348)
20. ShankavaramUT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007;6:820-32. (Pubitemid 46554552)
21. Park IC, Lee SH, Whang DY, Hong WS, Choi SS, Shin HS, et al. Expression of a novel Bcl-2 related gene, B fl -1, in various human cancers and cancer cell lines. Anticancer Res 1997;17: 4619-22. (Pubitemid 28081755)
22. Karsan A, Yee E, Harlan JM. Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member,A1. JBiol Chem 1996;271:27201-4. (Pubitemid 26367264)
23. He BP, Wang JJ, Zhang X, Wu Y, Wang M, Bay BH, et al. Differential reactions of microglia to brain metastasis of lung cancer. Mol Med 2006;12:161- 70.
24. Cruz-Munoz W, Kerbel RS. Preclinical approaches to study the biology and treatment of brain metastases. Semin Cancer Biol 2011;21: 123-30.
25. Steeg PS,Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011;11:352-63.
26. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
27. Demunter A, De Wolf-Peeters C, Degreef H, Stas M, van den Oord JJ. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 2001;438:485-91. (Pubitemid 32449057)
28. Lahav R, Suva ML, Rimoldi D, Patterson PH, Stamenkovic I. Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas. Cancer Res 2004;64:8945-53. (Pubitemid 39665502)
29. Bagnato A, Rosano L, Spinella F, Di Castro V, Tecce R, Natali PG. Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 2004;64:1436-43. (Pubitemid 38235614)
30. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, et al. Activation of STAT3 in human melanoma promotes brain metastasis. Cancer Res 2006;66:3188-96.
31. Zhang C, Zhang F, Tsan R, Fidler IJ. Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. Cancer Res 2009;69:828-35.
32. Rolland Y, Demeule M, Fenart L, Beliveau R. Inhibition of melanoma brain metastasis by targeting melanotransferrin at the cell surface. Pigment Cell Melanoma Res 2009;22:86-98.
33. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo . Proc Natl Acad Sci U S A 1999;96: 11496-500. (Pubitemid 29487409)
34. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011;11:135- 41.
35. Wong ET, Berkenblit A. The role of topotecan in the treatment of brain metastases. Oncologist 2004;9:68-79. (Pubitemid 38134015)
36. Cranmer LD, Trevor KT, Bandlamuri S, Hersh EM. Rodent models of brain metastasis in melanoma. Melanoma Res 2005;15: 325-56. (Pubitemid 41558944)
37. Ohlstein EH, Nambi P, Hay DW, Gellai M, Brooks DP, Luengo J, et al. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-af fi nity and selective nonpeptide ETA receptor antagonist. J Pharmacol Exp Ther 1998; 286:650 - 6.
38. Wu-Wong JR, Dixon DB, Chiou WJ, Sorensen BK, Liu G, Jae HS, et al. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. Clin Sci (Lond) 2002;103 (Suppl 48:)107S-11S.
39. Chen EI, Hewel J, Krueger JS, Tiraby C, Weber MR, Kralli A 3rd, et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 2007;67:1472-86. (Pubitemid 46383371)